A Cohort Study of the Prognostic Impact of Exon-16 EZH2 Mutations in a Mexican-Mestizo Population of Patients with Diffuse Large B-Cell Lymphoma
Background: Novel prognostic factors in patients with diffuse large B-cell lymphoma (DLBCL) are required in the era of Rituximab. Objective: The objective of the study was to study the prognostic impact of exon-16 enhancer-of-zeste homolog-2 (EZH2) mutations in patients with DLBCL. Methods: In a coh...
Guardado en:
Autores principales: | Luis F. Oñate-Ocaña, Mayra Ponce-Martínez, Lucia Taja-Chayeb, Olga Gutiérrez-Hernández, Alejandro Avilés-Salas, David Cantú-de-León, Alfonso Dueñas-González, Myrna Candelaria-Hernández |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Permanyer
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/6513ee05ea0740fd8c68b39e553d4c10 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
A Decade of Lymphoma-Associated Hemophagocytic Lymphohistiocytosis: Does the Outcome Improve?
por: Cheng-Hsien Lin, et al.
Publicado: (2021) -
The Results and Outcomes of Rectal Cancer Treatment in the Era of Adjuvant Chemoradiation
por: Ahmad Izadpanah, et al.
Publicado: (2019) -
Sarcopenia’s Prognostic Impact on Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
por: Donggun Lee, et al.
Publicado: (2021) -
Pre-Existing Diabetes Limits Survival Rate After Immune Checkpoint Inhibitor Treatment for Advanced Lung Cancer: A Retrospective Study in Japan
por: Hisanaga K, et al.
Publicado: (2021) -
Immunohistochemistry for Thymidine Kinase-1 (TK1): A Potential Tool for the Prognostic Stratification of Breast Cancer Patients
por: Giuseppe Nicolò Fanelli, et al.
Publicado: (2021)